CHAMPIONS ONCOLOGY INC (CSBR) Stock Fundamental Analysis
USA - NASDAQ:CSBR - US15870P3073 - Common Stock
6.565 USD
-0.13 (-2.01%)
6.3214 USD
-0.24 (-3.71%)
We assign a fundamental rating of 5 out of 10 to CSBR. CSBR was compared to 55 industry peers in the Life Sciences Tools & Services industry. CSBR has only an average score on both its financial health and profitability. CSBR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
CSBR had positive earnings in the past year.
CSBR had a positive operating cash flow in the past year.
In multiple years CSBR reported negative net income over the last 5 years.
In multiple years CSBR reported negative operating cash flow during the last 5 years.
1.2 Ratios
CSBR has a Return On Assets of 14.53%. This is amongst the best in the industry. CSBR outperforms 92.73% of its industry peers.
With an excellent Return On Equity value of 124.63%, CSBR belongs to the best of the industry, outperforming 98.18% of the companies in the same industry.
CSBR has a Return On Invested Capital of 45.09%. This is amongst the best in the industry. CSBR outperforms 98.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.53% | ||
| ROE | 124.63% | ||
| ROIC | 45.09% |
ROA(3y)-9.62%
ROA(5y)-5.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 8.26%, CSBR is in the better half of the industry, outperforming 70.91% of the companies in the same industry.
In the last couple of years the Profit Margin of CSBR has grown nicely.
Looking at the Operating Margin, with a value of 8.51%, CSBR is in the better half of the industry, outperforming 63.64% of the companies in the same industry.
CSBR's Operating Margin has improved in the last couple of years.
CSBR has a Gross Margin of 50.15%. This is comparable to the rest of the industry: CSBR outperforms 54.55% of its industry peers.
In the last couple of years the Gross Margin of CSBR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.51% | ||
| PM (TTM) | 8.26% | ||
| GM | 50.15% |
OM growth 3Y89.93%
OM growth 5YN/A
PM growth 3Y94.62%
PM growth 5YN/A
GM growth 3Y-1.13%
GM growth 5Y1.11%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CSBR is creating value.
CSBR has more shares outstanding than it did 1 year ago.
CSBR has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CSBR has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.64, we must say that CSBR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CSBR (0.64) is worse than 63.64% of its industry peers.
CSBR has a debt to FCF ratio of 0.03. This is a very positive value and a sign of high solvency as it would only need 0.03 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.03, CSBR belongs to the top of the industry, outperforming 92.73% of the companies in the same industry.
CSBR has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.02, CSBR is in the better half of the industry, outperforming 65.45% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.03 | ||
| Altman-Z | 0.64 |
ROIC/WACC4.31
WACC10.45%
2.3 Liquidity
CSBR has a Current Ratio of 0.94. This is a bad value and indicates that CSBR is not financially healthy enough and could expect problems in meeting its short term obligations.
CSBR's Current ratio of 0.94 is on the low side compared to the rest of the industry. CSBR is outperformed by 90.91% of its industry peers.
A Quick Ratio of 0.94 indicates that CSBR may have some problems paying its short term obligations.
With a Quick ratio value of 0.94, CSBR is not doing good in the industry: 85.45% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.94 | ||
| Quick Ratio | 0.94 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 263.16% over the past year.
The Earnings Per Share has been growing by 146.62% on average over the past years. This is a very strong growth
Looking at the last year, CSBR shows a quite strong growth in Revenue. The Revenue has grown by 13.54% in the last year.
The Revenue has been growing by 12.13% on average over the past years. This is quite good.
EPS 1Y (TTM)263.16%
EPS 3Y146.62%
EPS 5YN/A
EPS Q2Q%-127.27%
Revenue 1Y (TTM)13.54%
Revenue growth 3Y5.06%
Revenue growth 5Y12.13%
Sales Q2Q%-0.43%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
Based on estimates for the next years, CSBR will show a quite strong growth in Revenue. The Revenue will grow by 18.26% on average per year.
EPS Next Y-50.13%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year7.8%
Revenue Next 2Y18.91%
Revenue Next 3Y18.44%
Revenue Next 5Y18.26%
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 21.18 indicates a rather expensive valuation of CSBR.
83.64% of the companies in the same industry are more expensive than CSBR, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.38, CSBR is valued a bit cheaper.
With a Price/Forward Earnings ratio of 29.26, CSBR can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, CSBR is valued a bit cheaper than 65.45% of the companies in the same industry.
CSBR is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.86, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.18 | ||
| Fwd PE | 29.26 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CSBR is valued cheaper than 94.55% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CSBR indicates a rather cheap valuation: CSBR is cheaper than 96.36% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.94 | ||
| EV/EBITDA | 12.48 |
4.3 Compensation for Growth
CSBR has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
CSBR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
6.565
-0.13 (-2.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners49.54%
Inst Owner Change-2.44%
Ins Owners25.91%
Ins Owner Change0%
Market Cap90.53M
Analysts82.86
Price Target12.24 (86.44%)
Short Float %0.85%
Short Ratio2.52
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1847.55%
Min EPS beat(2)65.69%
Max EPS beat(2)3629.41%
EPS beat(4)4
Avg EPS beat(4)1136.19%
Min EPS beat(4)65.69%
Max EPS beat(4)3629.41%
EPS beat(8)6
Avg EPS beat(8)555.12%
EPS beat(12)7
Avg EPS beat(12)315.97%
EPS beat(16)9
Avg EPS beat(16)235.26%
Revenue beat(2)2
Avg Revenue beat(2)15%
Min Revenue beat(2)0.83%
Max Revenue beat(2)29.17%
Revenue beat(4)4
Avg Revenue beat(4)8.88%
Min Revenue beat(4)0.83%
Max Revenue beat(4)29.17%
Revenue beat(8)5
Avg Revenue beat(8)1.71%
Revenue beat(12)7
Avg Revenue beat(12)1.03%
Revenue beat(16)10
Avg Revenue beat(16)1%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-116.67%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.18 | ||
| Fwd PE | 29.26 | ||
| P/S | 1.59 | ||
| P/FCF | 12.94 | ||
| P/OCF | 12.26 | ||
| P/B | 24 | ||
| P/tB | 26.34 | ||
| EV/EBITDA | 12.48 |
EPS(TTM)0.31
EY4.72%
EPS(NY)0.22
Fwd EY3.42%
FCF(TTM)0.51
FCFY7.73%
OCF(TTM)0.54
OCFY8.16%
SpS4.13
BVpS0.27
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.53% | ||
| ROE | 124.63% | ||
| ROCE | 57.07% | ||
| ROIC | 45.09% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 8.51% | ||
| PM (TTM) | 8.26% | ||
| GM | 50.15% | ||
| FCFM | 12.29% |
ROA(3y)-9.62%
ROA(5y)-5.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y89.93%
OM growth 5YN/A
PM growth 3Y94.62%
PM growth 5YN/A
GM growth 3Y-1.13%
GM growth 5Y1.11%
F-Score6
Asset Turnover1.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.03 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 23.72% | ||
| Cap/Sales | 0.68% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.88% | ||
| Profit Quality | 148.84% | ||
| Current Ratio | 0.94 | ||
| Quick Ratio | 0.94 | ||
| Altman-Z | 0.64 |
F-Score6
WACC10.45%
ROIC/WACC4.31
Cap/Depr(3y)65.35%
Cap/Depr(5y)124.01%
Cap/Sales(3y)2.56%
Cap/Sales(5y)4.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)263.16%
EPS 3Y146.62%
EPS 5YN/A
EPS Q2Q%-127.27%
EPS Next Y-50.13%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)13.54%
Revenue growth 3Y5.06%
Revenue growth 5Y12.13%
Sales Q2Q%-0.43%
Revenue Next Year7.8%
Revenue Next 2Y18.91%
Revenue Next 3Y18.44%
Revenue Next 5Y18.26%
EBIT growth 1Y170.05%
EBIT growth 3Y99.53%
EBIT growth 5YN/A
EBIT Next Year-7.31%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y200.34%
FCF growth 3Y19.31%
FCF growth 5Y58.93%
OCF growth 1Y220.35%
OCF growth 3Y4.35%
OCF growth 5Y20.48%